1.49 Student Questions, Boeing 737 Max, Pancreatic Surveillance, Leukemia Drugs with Dr. Elihu Estey

Plenary Session

Vinay Prasad, MD MPH

Policy, Oncology, Science & Medicine, Medicine, Health

4.8 • 798 Ratings

🗓️ 22 March 2019

⏱️ 115 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

We begin this episode by answering questions from a med student who is a Plenary Session fan. We transition from there to a discussion of the recent news stories on the FAA's handling of the Boeing 737 Max controversy and how this reflects on other USA regulatory agencies like the FDA. After a critique of the recent paper "Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance" published in the Journal of Clinical Oncology, we end with an interview with Dr. Elihu Estey of the University of Washington on his 40 years of experience as an oncologist, the "Renaissance" of drugs for leukemia, and advice for trainees on how to approach career goals. Pancreatic Surveillance: doi.org/10.1200/JCO.18.01512 Back us on Patreon! www.patreon.com/plenarysession

Transcript

Click on a timestamp to play from that location

0:00.0	You're listening to Plenary Session.
0:09.4	This week on Plenary Session, we have a few things for you.
0:12.7	First, a listener has asked me several questions, and I'm going to read them aloud on the podcast and do my very best to respond to them.
0:20.2	Next, I'm going to talk about something that's outside of medicine,
0:24.7	the Boeing 737 Max, and news stories that suggest the very cozy relationship
0:31.5	between Boeing executives and the FAA,
0:34.8	and the revelation that the FAA asked Boeing to essentially inspect their own plane.
0:42.9	And what does this mean for the other regulatory agencies that are supposed to be protecting
0:48.0	the public, such as the U.S. FDA?
0:51.6	Finally, I'm going to talk about a very interesting paper entitled Deleterious Germline Mutations
0:57.9	are a risk factor for neoplastic progression among high-risk individuals undergoing pancreatic
1:03.8	surveillance.
1:04.7	This is one of those papers that reminds you to never let the data get in the way of the story
1:09.3	you wish to tell.
1:10.1	And finally, I have an interview with none other than Eli Esty.
1:15.7	Dr. Esty is a renowned leukemia expert at Seattle Fred Hutch Cancer Center.
1:20.7	He has over 40 years of experience as an oncologist taking care of leukemia patients,
1:26.1	and he's going to share his insights into
1:29.1	recent approvals in leukemia, the quote-unquote renaissance of drugs in the leukemia space,
1:35.4	and some advice for young trainees on how they should be thinking about what they want to get out
1:40.7	of their careers. So you won't want to miss this. Stay tuned.
1:46.2	But first, a plug.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Vinay Prasad, MD MPH, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vinay Prasad, MD MPH and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.